Anti-vascular endothelial growth factor for neovascular glaucoma

医学 致盲 眼压 眼科 随机对照试验 贝伐单抗 临床试验 青光眼 梅德林 眼内炎 验光服务 外科 内科学 化疗 政治学 法学
作者
Thanitsara Rittiphairoj,Gloria Roberti,Manuele Michelessi
出处
期刊:The Cochrane library [Elsevier]
卷期号:2023 (6) 被引量:9
标识
DOI:10.1002/14651858.cd007920.pub4
摘要

Background Neovascular glaucoma (NVG) is a potentially blinding, secondary glaucoma. It is caused by the formation of abnormal new blood vessels, which prevent normal drainage of aqueous from the anterior segment of the eye. Anti‐vascular endothelial growth factor (anti‐VEGF) medications are specific inhibitors of the primary mediators of neovascularization. Studies have reported the effectiveness of anti‐VEGF medications for the control of intraocular pressure (IOP) in NVG. Objectives To assess the effectiveness of intraocular anti‐VEGF medications, alone or with one or more types of conventional therapy, compared with no anti‐VEGF medications for the treatment of NVG. Search methods We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register); MEDLINE; Embase; PubMed; and LILACS to 19 October 2021; metaRegister of Controlled Trials to 19 October 2021; and two additional trial registers to 19 October 2021. We did not use any date or language restrictions in the electronic search for trials. Selection criteria We included randomized controlled trials (RCTs) of people treated with anti‐VEGF medications for NVG. Data collection and analysis Two review authors independently assessed the search results for trials, extracted data, and assessed risk of bias, and the certainty of the evidence. We resolved discrepancies through discussion. Main results We included five RCTs (356 eyes of 353 participants). Each trial was conducted in a different country: two in China, and one each in Brazil, Egypt, and Japan. All five RCTs included both men and women; the mean age of participants was 55 years or older. Two RCTs compared intravitreal bevacizumab combined with Ahmed valve implantation and panretinal photocoagulation (PRP) with Ahmed valve implantation and PRP alone. One RCT randomized participants to receive an injection of either intravitreal aflibercept or placebo at the first visit, followed by non‐randomized treatment according to clinical findings after one week. The remaining two RCTs randomized participants to PRP with and without ranibizumab, one of which had insufficient details for further analysis. We assessed the RCTs to have an unclear risk of bias for most domains due to insufficient information to permit judgment. Four RCTs examined achieving control of IOP, three of which reported our time points of interest. Only one RCT reported our critical time point at one month; it found that the anti‐VEGF group had a 1.3‐fold higher chance of achieving control of IOP at one month (RR 1.32, 95% 1.10 to 1.59; 93 participants) than the non‐anti‐VEGF group (low certainty of evidence). For other time points, one RCT found a three‐fold greater achievement in control of IOP in the anti‐VEGF group when compared with the non‐anti‐VEGF group at one year (RR 3.00; 95% CI:1.35 to 6.68; 40 participants). However, another RCT found an inconclusive result at the time period ranging from 1.5 years to three years (RR 1.08; 95% CI: 0.67 to 1.75; 40 participants). All five RCTs examined mean IOP, but at different time points. Very‐low‐certainty evidence showed that anti‐VEGFs were effective in reducing mean IOP by 6.37 mmHg (95% CI: ‐10.09 to ‐2.65; 3 RCTs; 173 participants) at four to six weeks when compared with no anti‐VEGFs. Anti‐VEGFs may reduce mean IOP at three months (MD ‐4.25; 95% CI ‐12.05 to 3.54; 2 studies; 75 participants), six months (MD ‐5.93; 95% CI ‐18.13 to 6.26; 2 studies; 75 participants), one year (MD ‐5.36; 95% CI ‐18.50 to 7.77; 2 studies; 75 participants), and more than one year (MD ‐7.05; 95% CI ‐16.61 to 2.51; 2 studies; 75 participants) when compared with no anti‐VEGFs, but such effects remain uncertain. Two RCTs reported the proportion of participants who achieved an improvement in visual acuity with specified time points. Participants receiving anti‐VEGFs had a 2.6 times (95% CI 1.60 to 4.08; 1 study; 93 participants) higher chance of improving visual acuity when compared with those not receiving anti‐VEGFs at one month (very low certainty of evidence). Likewise, another RCT found a similar result at 18 months (RR 4.00, 95% CI 1.33 to 12.05; 1 study; 40 participants). Two RCTs reported the outcome, complete regression of new iris vessels, at our time points of interest. Low‐certainty evidence showed that anti‐VEGFs had a nearly three times higher chance of complete regression of new iris vessels when compared with no anti‐VEGFs (RR 2.63, 95% CI 1.65 to 4.18; 1 study; 93 participants). A similar finding was observed at more than one year in another RCT (RR 3.20, 95% CI 1.45 to 7.05; 1 study; 40 participants). Regarding adverse events, there was no evidence that the risks of hypotony and tractional retinal detachment were different between the two groups (RR 0.67; 95% CI: 0.12 to 3.57 and RR 0.33; 95% CI: 0.01 to 7.72, respectively; 1 study; 40 participants). No RCTs reported incidents of endophthalmitis, vitreous hemorrhage, no light perception, and serious adverse events. Evidence for the adverse events of anti‐VEGFs was low due to limitations in the study design due to insufficient information to permit judgments and imprecision of results due to the small sample size. No trial reported the proportion of participants with relief of pain and resolution of redness at any time point. Authors' conclusions Anti‐VEGFs as an adjunct to conventional treatment could help reduce IOP in NVG in the short term (four to six weeks), but there is no evidence that this is likely in the longer term. Currently available evidence regarding the short‐ and long‐term effectiveness and safety of anti‐VEGFs in achieving control of IOP, visual acuity, and complete regression of new iris vessels in NVG is insufficient. More research is needed to investigate the effect of these medications compared with, or in addition to, conventional surgical or medical treatment in achieving these outcomes in NVG.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
没有蛀牙发布了新的文献求助10
刚刚
NJSGSKL完成签到,获得积分20
1秒前
科研狗完成签到 ,获得积分10
3秒前
gar发布了新的文献求助10
3秒前
nenoaowu发布了新的文献求助10
4秒前
欣慰的海豚完成签到,获得积分10
4秒前
可爱的函函应助自然卷采纳,获得10
6秒前
爆米花应助安详的冷安采纳,获得10
6秒前
6秒前
胡说八道完成签到 ,获得积分10
10秒前
10秒前
积极觅海发布了新的文献求助10
11秒前
12秒前
海的海完成签到 ,获得积分10
13秒前
舒心的南珍完成签到,获得积分10
13秒前
15秒前
15秒前
15秒前
畅跑daily完成签到,获得积分10
15秒前
风云完成签到,获得积分10
16秒前
赖晨靓发布了新的文献求助10
17秒前
17秒前
风云发布了新的文献求助10
20秒前
要减肥发布了新的文献求助10
20秒前
zyn发布了新的文献求助10
20秒前
Lucas应助NJSGSKL采纳,获得10
22秒前
24秒前
传奇3应助WangXiaoze采纳,获得10
25秒前
小蘑菇应助科研通管家采纳,获得30
25秒前
Owen应助科研通管家采纳,获得10
25秒前
研友_VZG7GZ应助科研通管家采纳,获得10
25秒前
共享精神应助科研通管家采纳,获得10
25秒前
Lucas应助科研通管家采纳,获得10
25秒前
26秒前
26秒前
26秒前
26秒前
26秒前
27秒前
科目三应助kuokyt采纳,获得10
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976253
求助须知:如何正确求助?哪些是违规求助? 3520405
关于积分的说明 11203301
捐赠科研通 3257028
什么是DOI,文献DOI怎么找? 1798589
邀请新用户注册赠送积分活动 877755
科研通“疑难数据库(出版商)”最低求助积分说明 806521